|
Date: 21 June 2022
Time: 11am - 12:30pm Panel discussion: "How to make collaborations between industry and researchers successful" Format: Zoom Webinar (registration is required) Hosted by: Shigeki SUGII, IMCB & Secretary, SCSS |
Panelists' information
|
Benjamin BORGO
Merck Team Leader, Genome Engineering and Modulation |
|
Bio
Benjamin Borgo currently leads a team of forward-thinking product and service managers within Merck KGaA’s Genome Engineering and Modulation franchise. His first exposure to CRISPR-based genome editing was as a graduate student where he attempted to engineer novel protein variants. Though he met with little success, it inspired a passion for CRISPR technology which he has brought with him to his current role within a company that is laser-focused on developing and utilizing revolutionary genome editing technologies. Prior to joining Merck KGaA, he has worked in various commercial and technical roles at Berkeley Light Inc., Agilent Technologies, Nanopore Diagnostics, and several small start-up companies focused on software applications. Ben has a PhD in computational biology from Washington University in St. Louis.
Benjamin Borgo currently leads a team of forward-thinking product and service managers within Merck KGaA’s Genome Engineering and Modulation franchise. His first exposure to CRISPR-based genome editing was as a graduate student where he attempted to engineer novel protein variants. Though he met with little success, it inspired a passion for CRISPR technology which he has brought with him to his current role within a company that is laser-focused on developing and utilizing revolutionary genome editing technologies. Prior to joining Merck KGaA, he has worked in various commercial and technical roles at Berkeley Light Inc., Agilent Technologies, Nanopore Diagnostics, and several small start-up companies focused on software applications. Ben has a PhD in computational biology from Washington University in St. Louis.
|
Geoff MCDERMOTT
10x Genomics Science and Technology Advisor, Australia |
|
Bio
Geoff McDermott has spent his career working at the crossroads of chemistry, biology, and microfluidics to help drive early-stage research concepts into successful scientific ventures. He earned his BSc in Forensic Science and his PhD in Chemistry from Deakin University, Australia. Geoff is an early-stage employee of 10x Genomics and is currently a Science and Technology Advisor based in Australia. Prior to this role, he held a senior position within R&D at 10x Genomics, where he was part of the product development team commercializing single cell products.
Geoff McDermott has spent his career working at the crossroads of chemistry, biology, and microfluidics to help drive early-stage research concepts into successful scientific ventures. He earned his BSc in Forensic Science and his PhD in Chemistry from Deakin University, Australia. Geoff is an early-stage employee of 10x Genomics and is currently a Science and Technology Advisor based in Australia. Prior to this role, he held a senior position within R&D at 10x Genomics, where he was part of the product development team commercializing single cell products.
|
Ryan LIM
Thermo Fisher Scientific Business Development Manager; Cell and Gene Therapy; IPAC Region |
|
BIO
As Thermo Fisher Scientific business development manager for the cell and gene therapy portfolio, Ryan Lim's primary function is to partner with and assist cell and gene therapy groups to accelerate their therapies toward their clinical applications for the IPAC region. Preceding this role, he was a field application scientist supporting the entire immunoassay portfolio in the Asia Pacific and Japan (APJ) region, providing onsite technical support as well as application development with key customers across the region. He subsequently expanded his role and was a technical sales specialist covering both the entire immunoassay and the Cell & Gene Therapy portfolio for the APJ region, whereby, in addition to technical support, he also worked with various academic and government researchers, CRO, CDMO and various biotech companies to develop integrated workflow solution to accelerate their work and address their roadblocks.
Prior to joining Thermo Fisher Scientific, he spent 6 years in academic research at the National University of School (School of medicine), focusing on drug development, and has expertise in cellular, animal, and clinical work.
As Thermo Fisher Scientific business development manager for the cell and gene therapy portfolio, Ryan Lim's primary function is to partner with and assist cell and gene therapy groups to accelerate their therapies toward their clinical applications for the IPAC region. Preceding this role, he was a field application scientist supporting the entire immunoassay portfolio in the Asia Pacific and Japan (APJ) region, providing onsite technical support as well as application development with key customers across the region. He subsequently expanded his role and was a technical sales specialist covering both the entire immunoassay and the Cell & Gene Therapy portfolio for the APJ region, whereby, in addition to technical support, he also worked with various academic and government researchers, CRO, CDMO and various biotech companies to develop integrated workflow solution to accelerate their work and address their roadblocks.
Prior to joining Thermo Fisher Scientific, he spent 6 years in academic research at the National University of School (School of medicine), focusing on drug development, and has expertise in cellular, animal, and clinical work.